RIBOLIA

Live / Applied — First extension granted (statement of use) (as of 09 Mar 2026)

What this means for you

Not registered yet, but its 30 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98928116
Mark type
Stylized text
Filed
30 Dec 2024
Published for opposition
15 Jul 2025
Attorney of record
Zhi Dong

Goods and services

  • Class 005 — Pharmaceuticals: medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceuticals for the treatment of cancer; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic foods and beverages adapted for medical use; depuratives for the body; veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; dressings, medical; composite materials for dental purposes; diapers for pets
  • Class 042 — Scientific and technological services: technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development services; research in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design

Owner

Prosecution history

  • 10 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 09 Mar 2026 — SOU EXTENSION 1 GRANTED
  • 09 Mar 2026 — SOU EXTENSION 1 FILED
  • 09 Mar 2026 — SOU TEAS EXTENSION RECEIVED
  • 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 15 Jul 2025 — PUBLISHED FOR OPPOSITION
  • 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 12 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 12 Jun 2025 — ASSIGNED TO EXAMINER
  • 28 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
  • 30 Dec 2024 — NEW APPLICATION ENTERED

View this trademark record on Marksy